Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Nipocalimab by Johnson & Johnson for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Likelihood of Approval
Nipocalimab is under clinical development by Johnson & Johnson and currently in Phase III for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)....
Guselkumab by Johnson & Johnson for Crohn's Disease (Regional Enteritis): Likelihood of Approval
Guselkumab is under clinical development by Johnson & Johnson and currently in Pre-Registration for Crohn's Disease (Regional Enteritis). According to...
Erdafitinib by Johnson & Johnson for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval
Erdafitinib is under clinical development by Johnson & Johnson and currently in Phase II for Squamous Non-Small Cell Lung Cancer....
Daratumumab by Johnson & Johnson for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Daratumumab is under clinical development by Johnson & Johnson and currently in Phase I for Chronic Lymphocytic Leukemia (CLL). According...
Gemcitabine by Johnson & Johnson for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer): Likelihood of Approval
Gemcitabine is under clinical development by Johnson & Johnson and currently in Phase III for Non Muscle Invasive Bladder Cancer...
Apalutamide by Johnson & Johnson for Salivary Gland Cancer: Likelihood of Approval
Apalutamide is under clinical development by Johnson & Johnson and currently in Phase II for Salivary Gland Cancer. According to...
Daratumumab by Johnson & Johnson for T-Cell Leukemia: Likelihood of Approval
Daratumumab is under clinical development by Johnson & Johnson and currently in Phase II for T-Cell Leukemia. According to GlobalData,...
Daratumumab by Johnson & Johnson for Primary Systemic Amyloidosis: Likelihood of Approval
Daratumumab is under clinical development by Johnson & Johnson and currently in Phase II for Primary Systemic Amyloidosis. According to...
Daratumumab by Johnson & Johnson for Lymphoma: Likelihood of Approval
Daratumumab is under clinical development by Johnson & Johnson and currently in Phase II for Lymphoma. According to GlobalData, Phase...
Daratumumab by Johnson & Johnson for Systemic Lupus Erythematosus: Likelihood of Approval
Daratumumab is under clinical development by Johnson & Johnson and currently in Phase II for Systemic Lupus Erythematosus. According to...
JNJ-8543 by Johnson & Johnson for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma): Likelihood of Approval
JNJ-8543 is under clinical development by Johnson & Johnson and currently in Phase I for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma). According...
JNJ-8543 by Johnson & Johnson for Follicular Lymphoma: Likelihood of Approval
JNJ-8543 is under clinical development by Johnson & Johnson and currently in Phase I for Follicular Lymphoma. According to GlobalData,...
JNJ-79635322 by Johnson & Johnson for Relapsed Multiple Myeloma: Likelihood of Approval
JNJ-79635322 is under clinical development by Johnson & Johnson and currently in Phase I for Relapsed Multiple Myeloma. According to...
JNJ-79635322 by Johnson & Johnson for Refractory Multiple Myeloma: Likelihood of Approval
JNJ-79635322 is under clinical development by Johnson & Johnson and currently in Phase I for Refractory Multiple Myeloma. According to...
JNJ-8543 by Johnson & Johnson for Splenic Marginal Zone B-Cell Lymphoma: Likelihood of Approval
JNJ-8543 is under clinical development by Johnson & Johnson and currently in Phase I for Splenic Marginal Zone B-Cell Lymphoma....
Erdafitinib by Johnson & Johnson for Non-Small Cell Lung Cancer: Likelihood of Approval
Erdafitinib is under clinical development by Johnson & Johnson and currently in Phase II for Non-Small Cell Lung Cancer. According...
Daratumumab by Johnson & Johnson for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval
Daratumumab is under clinical development by Johnson & Johnson and currently in Phase II for Acute Lymphocytic Leukemia (ALL, Acute...
Daratumumab by Johnson & Johnson for Lymphoblastic Lymphoma: Likelihood of Approval
Daratumumab is under clinical development by Johnson & Johnson and currently in Phase II for Lymphoblastic Lymphoma. According to GlobalData,...
JNJ-4703 by Johnson & Johnson for Atopic Dermatitis (Atopic Eczema): Likelihood of Approval
JNJ-4703 is under clinical development by Johnson & Johnson and currently in Phase II for Atopic Dermatitis (Atopic Eczema). According...
Risk adjusted net present value: What is the current valuation of Johnson & Johnson's Gemcitabine?
Gemcitabine is a small molecule commercialized by Johnson & Johnson, with a leading Phase III program in Non Muscle Invasive...